Sometime in the next eleven weeks, FDA is expected to rule on CagriSema — Novo Nordisk's fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, the GLP-1 behind Ozempic and Wegovy. The NDA was filed December 18, 2025; company guidance and the standard 10-to-12-month review clock both point to a decision in the fourth quarter of 2026, and as of mid-year the drug was not approved anywhere in the world.
If approved, CagriSema becomes the first once-weekly GLP-1 plus amylin combination on the market — a mechanism neither tirzepatide (GLP-1/GIP) nor any current single-agent offers. The REDEFINE phase 3 program reported 22.7% mean weight loss at 84 weeks in obesity trials, which would be the largest figure for an approved obesity therapy to date. This piece is the state of play heading into the decision: what is known, what the head-to-head data against Zepbound actually showed, and what approval would and would not change.
The filing and the clock
Novo filed the CagriSema NDA on December 18, 2025, on the strength of the REDEFINE program: roughly 22.7% mean weight loss at 84 weeks in obesity trials, with a safety profile consistent with the parent molecules. Drugs.com's approval-history tracker and BioSpace's filing coverage both place the decision in Q4 2026. Novo has separately said a phase 3 trial of a higher-dose CagriSema regimen (2.4 mg cagrilintide / 7.2 mg semaglutide) is planned for the second half of 2026 — evidence the company sees headroom above the filed dose.
A Q4 decision does not guarantee a Q4 launch, but it does start the clock on everything downstream: label scope (obesity only, or overweight with comorbidities), dosing and titration instructions, and the pricing announcement that will define the next round of the access debate.
The head-to-head everyone argues about
CagriSema's REDEFINE-4 compared it directly against tirzepatide (Zepbound), and the readout produced genuinely divided coverage — not a triviality in a market where headlines move prescribing. NewsNation reported in September that CagriSema "outperforms Zepbound" on weight loss; Drug Discovery World's February assessment called the head-to-head a disappointment against expectations. Both describe the same data release: CagriSema numerically ahead on weight loss, with margins and statistical framing that let two outlets reach opposite conclusions.
Our CagriSema vs tirzepatide and CagriSema vs semaglutide comparisons walk the trial data side by side. The honest summary: CagriSema's headline number is the biggest reported, the head-to-head margin over tirzepatide is where the argument lives, and a final label will constrain which claims the manufacturer can actually make.
What approval would not change
Two things stay true regardless of the decision. First, approval would put CagriSema squarely in the approved-drug lane — which, since FDA's April 30, 2026 proposal to permanently exclude semaglutide, tirzepatide and liraglutide from compounding eligibility, is a lane with a closing gray-market door. A newly approved combination containing semaglutide would follow the same trajectory: shortage rules no longer shelter compounded copies, and enforcement attention on unapproved GLP-1 versions has been escalating all year.
Second, none of the numbers above are a recommendation for any individual. A 22.7% trial mean is a population statistic assembled under protocol conditions with run-in periods, structured titration and diet support. It is not a forecast for any one person, and the side-effect and discontinuation data in the same trials is part of the picture. Our regulatory timeline carries the decision when it lands, and the comparison pages will be updated the same week.